UroToday

EAU 2026: Final Analysis of the Phase 1 First-in-Human Study of an Erdafitinib Intravesical Drug-Releasing System in Patients with NMIBC Harboring Select FGFR A…

Over a median follow-up in responders of 18.0 months (range 15-21), the median duration of complete response was 18.0 months ...
UroToday

EAU 2026: Case-Based Panel Discussion Beyond Platinum: Evolving Frontlines in mUC: Where Do ADCs Fit in the Sequencing?

Dr. Matthew Galsky participated in the Case-based panel discussion Beyond platinum: Evolving frontlines in mUC and discussed where ADCs fit in the sequencing. Dr. Galsky began by emphasizing the rapid ...
UroToday

EAU 2026: Impact of 89Zr-girentuximab PET Versus Conventional Imaging on Clinical Decision-making in Patients with Indeterminate Renal Masses (ZIRCON-X)

ZIRCON-X was designed as a post-hoc analysis of imaging data collected in the ZIRCON trial to evaluate how the incorporation of 89 Zr-girentuximab PET imaging could influence clinical management ...
UroToday

EAU 2026: [89Zr]Zr-girentuximab PET/CT in the Non-invasive Characterization of Indeterminate Renal Lesions: Initial Real-world Clinical Experience

The PET tracer [ 89 Zr]Zr-girentuximab targets carbonic anhydrase IX (CAIX), a hypoxia-inducible enzyme that is strongly expressed in clear cell renal cell carcinoma (ccRCC). CAIX expression is highly ...
UroToday

EAU 2026: Time-Dependent Survival Benefit of Enzalutamide + Radium-223 in mCRPC: Reconstructed Analysis of the PEACE-3 Trial

The 2026 European Association of Urology (EAU) annual meeting featured an advancement in metastatic castration resistant ...
UroToday

EAU 2026: Development of a Novel 68Ga-Labeled Radiotracer Targeting Carbonic Anhydrase IX for Diagnosis of Clear Cell Renal Cell Carcinoma

The CAIX targeting radiotracer 68 Ga-C1 was developed and validated through in vitro assays. Initially, the investigators ...
UroToday

EAU 2026: Optimizing the Timing of Docetaxel After Androgen Receptor Pathway Inhibitor Therapy: Development and Validation of a Novel Prognostic Model in mCR…

The 2026 European Association of Urology (EAU) annual meeting featured an advancing prognostics and therapeutics in ...
UroToday

EAU 2026: Debate: Optimal Management of De-Novo Oligometastatic Disease: Radiotherapy – Treat All You Can See

The 2026 European Association of Urology (EAU) annual meeting featured a plenary prostate cancer session and a presentation ...
UroToday

EAU 2026: CAPTAIN: Randomized Controlled Trial Evaluating MRI-Guided TULSA Versus Robotic Prostatectomy – Initial Perioperative Outcomes

The median fraction of the gland reaching ablative temperatures on intra-procedural MRI thermometry was 78% (IQR 71-85), with 68% of cases comprising whole gland ablation and 32% sub-total ablation: ...
UroToday

EAU 2026: External Validation of a Prognostic Risk Model for Overall Survival After Radium-223 Treatment in mCRPC

(UroToday.com) The 2026 European Association of Urology (EAU) annual meeting featured an advancement in metastatic castration resistant prostate cancer (mCRPC) therapy session and a presentation by Dr ...
UroToday

EAU 2026: Comparative Effectiveness of NAI +BCG versus Other Bladder-Sparing Therapies in BCG-Unresponsive NMIBC with CIS ± Ta/T1 Papillary Disease: An External Control Arm Study

After matching, standardized mean differences were <0.1 for all key covariates. NAI + BCG showed improved outcomes versus other bladder sparing therapies in the d-uo cohort, including increased ...
UroToday

EAU 2026: Safety and Skeletal Event Profile of Radium-223 Combined with Enzalutamide in mCRPC: A Multicenter Retrospective Analysis in Japan

Grade ≥3 hematologic toxicities were uncommon (anemia 6.1%, neutropenia 5.2%), and non-hematologic adverse events were rare. The absence of bone-modifying agents was the strongest predictor of ...